Shares of Merck KGaA (FRA:MRK) have been given an average recommendation of “Buy” by the twenty-two ratings firms that are covering the company, Marketbeat Ratings reports. Eleven equities research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. The average 12 month target price among analysts that have issued a report on the stock in the last year is €108.05 ($133.40).
A number of equities research analysts have issued reports on the stock. JPMorgan Chase & Co. set a €95.00 ($117.28) price target on shares of Merck KGaA and gave the company a “neutral” rating in a report on Monday, February 12th. UBS Group set a €120.00 ($148.15) price target on shares of Merck KGaA and gave the company a “buy” rating in a report on Friday. Warburg Research set a €115.00 ($141.98) price target on shares of Merck KGaA and gave the company a “buy” rating in a report on Friday. Kepler Capital Markets set a €115.00 ($141.98) price target on shares of Merck KGaA and gave the company a “buy” rating in a report on Monday, November 6th. Finally, DZ Bank reiterated a “buy” rating on shares of Merck KGaA in a research note on Monday, February 12th.
Merck KGaA (MRK) traded up €1.00 ($1.23) during mid-day trading on Tuesday, reaching €83.52 ($103.11). 568,716 shares of the company’s stock were exchanged. Merck KGaA has a one year low of €80.50 ($99.38) and a one year high of €115.00 ($141.98). The company has a market capitalization of $10,790.00 and a PE ratio of 19.56.
About Merck KGaA
MERCK Kommanditgesellschaft auf Aktien provides products in the healthcare, life science, and performance materials sectors worldwide. The company offers prescription medicines to treat colorectal cancer, head and neck tumors, multiple sclerosis, infertility, growth hormone disorders, cardiovascular disorders, diabetes, and thyroid disorders; diagnostics and prescription drugs for allergen immunotherapy; and biosimilars for oncology and inflammatory disorders.
Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.